Evidence map›Paper›PMID 40133063›Full record

ReviewCancer science2025

Differentiation of Cytotoxic CD8

Ryo Koyama-Nasu, Yangsong Wang, Hinata Miyano, Motoko Y Kimura

Abstract readReview
In one paragraph

Review in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ryo Koyama-NasuDepartment of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yangsong WangDepartment of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hinata MiyanoDepartment of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Motoko Y KimuraDepartment of Experimental Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID https://orcid.org/0000-0002-5607-5066

Funding

AMED-PRIME AMED JP223fa627003AMED-PRIME JP21gm6310024Daiichi Sankyo Foundation of Life Science, Institute for Advanced Academic Research Chiba UniversityMinistry of Education, Culture, Sports, Science, and Technology (MEXT Japan) Grants-in-Aid for Scientific Research 23K24441Ministry of Education, Culture, Sports, Science, and Technology (MEXT Japan) Grants-in-Aid for Scientific Research (B) 24K02259Ministry of Education, Culture, Sports, Science, and Technology (MEXT Japan) Grants-in-Aid for Scientific Research (C) 24K10374Projects for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development (AMED) JP18cm0106339Projects for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development (AMED) JP20cm01106372the Translational Research Program from AMED 24ym0126805j0003 A-228Transformative Research Areas (A) 22H05189
6 · The paper itself

Abstract

Tumor-specific CD8

Indexed as

Antigens, CDAntigens, Differentiation, T-LymphocyteCD8-Positive T-LymphocytesLectins, C-TypeNeoplasmsT-Lymphocytes, CytotoxicAnimalsCD69 AntigensCell DifferentiationDisease ProgressionHepatitis A Virus Cellular Receptor 2HumansTumor MicroenvironmentAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensHepatitis A Virus Cellular Receptor 2Lectins, C-TypeCD69chronic CD8+ T cell responsetumor‐draining lymph nodestumor‐specific CD8+ T cells

Identifiers

PMID40133063
PMCPMC12127096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.